DK4153232T3 - TNFalfa-immunkonjugatterapi til behandling af hjernetumorer - Google Patents
TNFalfa-immunkonjugatterapi til behandling af hjernetumorer Download PDFInfo
- Publication number
- DK4153232T3 DK4153232T3 DK21726426.6T DK21726426T DK4153232T3 DK 4153232 T3 DK4153232 T3 DK 4153232T3 DK 21726426 T DK21726426 T DK 21726426T DK 4153232 T3 DK4153232 T3 DK 4153232T3
- Authority
- DK
- Denmark
- Prior art keywords
- tnfalpha
- treatment
- brain tumors
- immunoconjugate therapy
- immunoconjugate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20176157 | 2020-05-22 | ||
| PCT/EP2021/063758 WO2021234178A1 (en) | 2020-05-22 | 2021-05-24 | TNFα IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4153232T3 true DK4153232T3 (da) | 2024-08-12 |
Family
ID=70802794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21726426.6T DK4153232T3 (da) | 2020-05-22 | 2021-05-24 | TNFalfa-immunkonjugatterapi til behandling af hjernetumorer |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11872288B2 (da) |
| EP (2) | EP4153232B1 (da) |
| JP (1) | JP7352040B2 (da) |
| CN (1) | CN115666645A (da) |
| AU (2) | AU2021276573B2 (da) |
| CA (1) | CA3177566C (da) |
| DK (1) | DK4153232T3 (da) |
| ES (1) | ES2987329T3 (da) |
| FI (1) | FI4153232T3 (da) |
| HR (1) | HRP20241274T1 (da) |
| HU (1) | HUE068804T2 (da) |
| LT (1) | LT4153232T (da) |
| PL (1) | PL4153232T3 (da) |
| PT (1) | PT4153232T (da) |
| RS (1) | RS65944B1 (da) |
| SI (1) | SI4153232T1 (da) |
| SM (1) | SMT202400493T1 (da) |
| WO (1) | WO2021234178A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65944B1 (sr) * | 2020-05-22 | 2024-10-31 | Philogen Spa | Terapija tnf-a imunokonjugatom za lečenje tumora mozga |
| CN118922207A (zh) | 2022-03-21 | 2024-11-08 | 菲洛根股份公司 | TNFα免疫缀合物制剂 |
| AU2023332212A1 (en) | 2022-09-01 | 2025-04-10 | Philogen S.P.A. | Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE526039T1 (de) | 2000-02-24 | 2011-10-15 | Philogen Spa | Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
| CA2400622A1 (en) | 2000-02-24 | 2001-08-30 | Eidgenossische Technische Hochschule Zurich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| RU2352582C2 (ru) * | 2002-01-03 | 2009-04-20 | Шеринг Акциенгезельшафт | Конъюгаты, содержащие антитело, специфическое для ed-в-домена фибронектина, и их применение для обнаружения и лечения опухолей |
| AU2003219370B2 (en) | 2002-03-11 | 2009-01-15 | Philogen S.P.A | Antibodies derived rom anti ED-B L19 and targeting tumor vasculature |
| EP1514561A1 (en) * | 2003-09-10 | 2005-03-16 | Philogen S.p.A. | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
| CA2577550C (en) * | 2004-08-25 | 2012-10-16 | The University Of Chicago | Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| ES2606490T3 (es) * | 2006-05-08 | 2017-03-24 | Philogen S.P.A. | Citocinas dirigidas por anticuerpos para terapia |
| CA2728739C (en) * | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| GB201612317D0 (en) * | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| GB201715008D0 (en) * | 2017-09-18 | 2017-11-01 | Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa | TRPV2 Antagonists |
| RS65944B1 (sr) * | 2020-05-22 | 2024-10-31 | Philogen Spa | Terapija tnf-a imunokonjugatom za lečenje tumora mozga |
-
2021
- 2021-05-24 RS RS20241036A patent/RS65944B1/sr unknown
- 2021-05-24 US US17/999,444 patent/US11872288B2/en active Active
- 2021-05-24 PT PT217264266T patent/PT4153232T/pt unknown
- 2021-05-24 SM SM20240493T patent/SMT202400493T1/it unknown
- 2021-05-24 WO PCT/EP2021/063758 patent/WO2021234178A1/en not_active Ceased
- 2021-05-24 PL PL21726426.6T patent/PL4153232T3/pl unknown
- 2021-05-24 EP EP21726426.6A patent/EP4153232B1/en active Active
- 2021-05-24 CA CA3177566A patent/CA3177566C/en active Active
- 2021-05-24 FI FIEP21726426.6T patent/FI4153232T3/fi active
- 2021-05-24 LT LTEPPCT/EP2021/063758T patent/LT4153232T/lt unknown
- 2021-05-24 CN CN202180036945.7A patent/CN115666645A/zh active Pending
- 2021-05-24 JP JP2022570616A patent/JP7352040B2/ja active Active
- 2021-05-24 HR HRP20241274TT patent/HRP20241274T1/hr unknown
- 2021-05-24 DK DK21726426.6T patent/DK4153232T3/da active
- 2021-05-24 ES ES21726426T patent/ES2987329T3/es active Active
- 2021-05-24 SI SI202130199T patent/SI4153232T1/sl unknown
- 2021-05-24 HU HUE21726426A patent/HUE068804T2/hu unknown
- 2021-05-24 AU AU2021276573A patent/AU2021276573B2/en active Active
- 2021-05-24 EP EP24170718.1A patent/EP4389146A3/en active Pending
-
2023
- 2023-10-03 US US18/480,153 patent/US12377161B2/en active Active
-
2024
- 2024-03-20 AU AU2024201834A patent/AU2024201834A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL4153232T3 (pl) | 2024-12-16 |
| CN115666645A (zh) | 2023-01-31 |
| EP4153232A1 (en) | 2023-03-29 |
| US12377161B2 (en) | 2025-08-05 |
| SMT202400493T1 (it) | 2025-01-14 |
| US11872288B2 (en) | 2024-01-16 |
| EP4153232B1 (en) | 2024-06-26 |
| JP7352040B2 (ja) | 2023-09-27 |
| EP4389146A2 (en) | 2024-06-26 |
| US20240197903A1 (en) | 2024-06-20 |
| PT4153232T (pt) | 2024-10-02 |
| AU2024201834A1 (en) | 2024-05-16 |
| FI4153232T3 (fi) | 2024-09-25 |
| AU2021276573B2 (en) | 2023-12-21 |
| CA3177566C (en) | 2024-01-02 |
| HRP20241274T1 (hr) | 2024-12-06 |
| HUE068804T2 (hu) | 2025-01-28 |
| SI4153232T1 (sl) | 2024-12-31 |
| LT4153232T (lt) | 2024-10-10 |
| AU2021276573A1 (en) | 2022-11-17 |
| JP2023522791A (ja) | 2023-05-31 |
| US20230233702A1 (en) | 2023-07-27 |
| CA3177566A1 (en) | 2021-11-25 |
| RS65944B1 (sr) | 2024-10-31 |
| ES2987329T3 (es) | 2024-11-14 |
| EP4389146A3 (en) | 2024-10-02 |
| WO2021234178A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4096717T3 (da) | Behandling af cancer | |
| DK4225297T3 (da) | Kombinationsbehandling til behandling af cancer | |
| PL3600309T3 (pl) | Skojarzenia terapeutyczne do leczenia chorób wątroby | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| DK4259796T3 (da) | Terapeutiske midler til behandlingen af neurodegenerative lidelser | |
| DK4153232T3 (da) | TNFalfa-immunkonjugatterapi til behandling af hjernetumorer | |
| DK3773738T3 (da) | Antistof-lægemiddelkonjugater og anvendelser deraf til behandling af cancer | |
| DK3778592T3 (da) | PSMA-målrettet radiolægemiddel til diagnosticering og behandling af prostatacancer | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| IL280510A (en) | Antibody-drug conjugates for use in the treatment of metastatic brain tumor | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| IL282311A (en) | Use of reboxetine to treat narcolepsy | |
| IL283265A (en) | Ex vivo organ treatment with peg-phospholipid molecules | |
| IL285155A (en) | Metal chelator combination therapy for the treatment of cancer | |
| HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
| HUE057197T2 (hu) | Eljárás nafta hirdogénezõ kezelésére | |
| IL319432A (en) | Methods of treating cancer | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| IL281600A (en) | Methods of treating cancer | |
| IL310870A (en) | Quinazoline compounds for treatment of disease | |
| EP4055033A4 (en) | Combination therapy to treat brain cancer | |
| DK4125842T3 (da) | Samtidig indgivelse af mirdametinib og lifirafenib til anvendelse til behandling af kræftformer | |
| EP4090369A4 (en) | PERICYTE-SPARKING THERAPY | |
| EP4440623A4 (en) | Polytherapy for the treatment of cancer | |
| LT4419526T (lt) | Heterocikliniai junginiai, skirti vėžiui gydyti |